Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

Royalty Pharma (RPRX) announced two major steps to enhance shareholder value. First, the Board of Directors has agreed to acquire its external manager, RP Management. This transaction to simplify ...

India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds across Big Pharma skyrocketed by 281%. In 2024, Fierce Biotech reported 192 ...

Novo Nordisk, for its part, is expected to jump from 10th place to sixth this year, according to Evaluate Pharma’s consensus forecasts. Nevertheless, it’s Roche that’s been tipped to stand ...

Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some of their best-selling drugs, according to a top M&A banker. Merck's cancer drug Keytruda ...

BERKELEY HEIGHTS, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") today announced ...

Veeda Group has unveiled a new logo and brand identity—Veeda Lifesciences—reflecting ... with reputable sponsors, including leading global pharma companies.